Take a pass on Celestica, says RBC Capital

Ahead of second quarter earnings from Celestica (Celestica Stock Quote, Chart, News TSX:CLS) analyst Paul Treiber of RBC Capital is sticking with his “Hold” rating on the stock.

Trieber issued an update on his coverage on Tuesday in which he set a target price of $7.50 per share, which is above analysts’ target consensus of $6.69.

Headquartered in Toronto, Celestica is an electronics manufacturing services company with an Advanced Technology Solutions (ATS) segment and Connectivity & Cloud Solutions (CCS) segment, the latter of which went through a review as part of a wider restructuring conducted by the company and featuring a disengagement from programs with Cisco Systems.

Celestica’s CCS segment saw its revenue drop last quarter due to demand softness from its communications customers, a state of affairs the company expects will continue into the second quarter, due on Wednesday July 29.

For its Q1 2020, Celestica reported total revenue down eight per cent year-over-year to $1.32 billion, with a five-per-cent drop in ATS revenue and a ten per cent decrease in CCS revenue. Adjusted earnings (non-IFRS) came in at $0.16 per share compared to $0.12 per share a year earlier. (All figures in US dollars except where noted otherwise.)

At the time, management spoke of the challenge currently being faced due to the COVID-19 pandemic, which has caused a decline in demand for Celestica’s products.

“While the full impact and duration of COVID-19 is unknown at this time, we believe Celestica’s swift response, diversification, improved operating model, and solid balance sheet position us well to weather this disruption. Despite the current challenges, our long-term goal to generate sustainable profitable growth remains unchanged,” said Rob Mionis, CEO and president, in a press release.

Year-to-date, Celestica’s share price is down 13 per cent. At press time, Trieber’s $7.50 target represented a projected 12-month return of 7.6 per cent.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: cls
Jayson MacLean

Jayson is a writer, researcher and educator with a PhD in political philosophy from the University of Ottawa. His interests range from bioethics and innovations in the health sciences to governance, social justice and the history of ideas.

Recent Posts

Is Dexterra Group a buy?

Its first quarter results are in the books and Beacon analyst Kirk Wilson has lowered his price target on Dexterra… [Read More]

20 mins ago

Is AYR stock a buy?

Following the company's first quarter results, Beacon analyst Russell Stanley has maintained his "Buy" rating on Ayr Wellness (Ayr Wellness… [Read More]

10 hours ago

Cresco Labs earns target raise at Echelon

Following the company's first quarter results, Echelon Capital Markets analyst Andrew Semple has raised his price target on Cresco Labs… [Read More]

12 hours ago

SSTI is a buy, Roth says

Its first quarter results are in the book and Roth MKM analyst Richard K Baldry is still bullish on SoundThinking… [Read More]

1 day ago

GLXY wins price target raise at ATB Capital

Following the company's first quarter results, ATB Capital Markets analyst Martin Toner has raised his price target on Galaxy Digital… [Read More]

1 day ago

Paradigm cuts price target on TTNM

Following first quarter results he describes as "mixed" Paradigm Capital analyst Alexandra Ricci has cut her price target on Titanium… [Read More]

1 day ago